Device Trial Radar · NCT03702192
EXCOR® Pediatric VAD Anticoagulation IDE
Last checked: Nov 20, 2026Latest source record: Oct 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Nov 2018
Primary completion
Nov 2018
Study completion Jan 17, 2019
Sponsor
- Lead sponsor
- David N. RosenthalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 10, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Berlin Heart EXCOR ventricular assist device received approval from the FDA as a bridge to transplantation for children in 2011. Successful bridge to transplantation or recovery in the IDE trial of the Berlin Heart EXCOR was 88% to 92%, but a high incidence of neurological injury was reported in this trial (29%). Stroke remains the most important complication of Berlin Heart EXCOR support, with high mortality rates, and considerable long-term morbidity. The EXCOR IDE study incorporated a novel anticoagulation protocol (henceforth referred to as the Edmonton Anticoagulation Protocol). The preponderance of ischemic strokes in this study raised the question of whether the anticoagulation protocol was sufficiently intensive, as ischemic strokes in this setting are virtually always thromboembolic phenomena. In response to these data and to the experience at the investigator's institution, a novel anticoagulation protocol has been devised for use with the EXCOR (Stanford anticoagulation protocol).The purpose of this study is to perform a pilot evaluation of this protocol in a multi--center setting, to prepare for a randomized trial between this and a subsequent iteration of anticoagulation treatment.
Conditions
- Pediatric HD
Interventions
novel anticoagulation protocol used in conjunction with the Berlin Heart EXCORDevice
novel antithrombotic management protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of major bleeding adverse events reported using the Stanford Anti-Thrombotic Protocol.Time frame: Up to 90 days
- Number of all forms of stroke events reported using the Stanford Anti-Thrombotic Protocol.Time frame: Up 90 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.